The U.S. Food and Drug Administration has approved Aranesp (darbepoetin alfa) by Amgen for the treatment of anemia associated with chronic renal failure. Aranesp requires fewer injections than the existing treatment for the condition, according to an Amgen release.
Aranesp was studied in 1,598 adults with chronic renal failure for a total of 942 patient years in 12 clinical trials. Results showed that patients receiving Aranesp consistently reached target hemoglobin levels and that Aranesp was well tolerated. Aranesp is contraindicated in patients with uncontrolled hypertension.
No comments:
Post a Comment